Showing 3211-3220 of 5773 results for "".
- Prevent Blindness Opens Nominations for the 2024 Jenny Pomeroy Award for Excellence in Vision and Public Health, and Rising Visionary Awardhttps://modernod.com/news/prevent-blindness-opens-nominations-for-the-2024-jenny-pomeroy-award-for-excellence-in-vision-and-public-health-and-rising-visionary-award/2482043/Prevent Blindness is issuing the call for nominations for the “2024 Jenny Pomeroy Award for Excellence in Vision and Public Health,” and the fifth annual “
- Ocuphire Pharma Receives FDA Agreement for Phase 3 Trial of Phentolamine Solution for Poor Night Visionhttps://modernod.com/news/ocuphire-pharma-receives-fda-agreement-for-phase-3-trial-of-phentolamine-solution-for-the-treatment-of-decreased-visual-acuity-under-dim-light-conditions/2482041/Ocuphire Pharma announced it has received agreement from the FDA under a special protocol assessment (SPA) for the clinical trial protocol and planned statistical analysis of the LYNX-2 phase 3 trial to evaluate phentolamine ophthalmic solution for the proposed indication for the treatm
- LumiThera Provides Update on FDA Review of Valeda Treatment for Dry AMD Patientshttps://modernod.com/news/lumithera-provides-update-on-fda-review-of-valeda-treatment-for-dry-amd-patients/2482040/LumiThera announced an update on the regulatory status of the Valeda Light Delivery System. Following feedback from the FDA, a De Novo request to reclassify the Valeda Light Delivery System as a Class II device has been submitted for review. Under the De Novo request process, the V
- Harrow Partners with Healthcare Market Access Technology Platforms to Support Launch of Vevyehttps://modernod.com/news/harrow-partners-with-healthcare-market-access-technology-platforms-to-support-launch-of-vevye/2482037/Harrow announced that it has partnered with three healthcare technology platforms to expand US availability of dry eye drug Vevye (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, twice-daily (BID) ophthalmic solution based on a water-free semifluorinated alkane (
- Iridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulationhttps://modernod.com/news/iridex-confirms-medicare-administrative-contractors-retired-local-coverage-determinations-that-restricted-cyclophotocoagulation/2482036/Iridex announced all five Medicare Administrative Contractors (MACs) retired their local coverage determinations (LCDs) that were scheduled to take effect on January 29, 2024. Iridex and other stakeholders opposing the LCDs have engaged with the MACs throughout the comment period to advocate
- Lupin Receives FDA Approval for Generic Loteprednol Etabonate Ophthalmic Suspensionhttps://modernod.com/news/lupin-receives-fda-approval-for-generic-loteprednol-etabonate-ophthalmic-suspension/2482032/Mumbai, India-based Lupin announced that it has received approval from the FDA for its abbreviated new drug application for Loteprednol etabonate ophthalmic suspension, 0.2%. The formuation is a generic equivalent to the reference listed drug Alrex Ophthalmic Suspension, 0.2%
- Visiox Pharmaceuticals to be Listed on Nasdaq Through Combination with PowerUp Acquisitionhttps://modernod.com/news/visiox-pharmaceuticals-to-be-listed-on-nasdaq-through-combination-with-powerup-acquisition/2482029/Visiox Pharmaceuticals and PowerUp Acquisition Corp. announced the execution of a definitive agreement for a business combination that would result in Visiox becoming a publicly traded company on the Nasdaq Capital Market. The business combination is expected to close in the first quarter of
- Cellusion Receives FDA Orphan Drug Designation for CLS001https://modernod.com/news/cellusion-receives-fda-orphan-drug-designation-for-cls001/2482028/Cellusion announced that the FDA has granted orphan drug designation to its regenerative medicine product, “iPS cell-derived corneal endothelial cell substitute,” (CLS001) for the treatment of bullous keratopathy. FDA grants orphan drug designation if the drug
- iSTAR Medical Continues European Expansion with First MINIject Surgeries in the Netherlandshttps://modernod.com/news/istar-medical-continues-european-expansion-with-first-miniject-surgeries-in-the-netherlands/2482027/iSTAR Medical announced the successful first implantations of MINIject, the company’s bio-integrating, minimally-invasive glaucoma surgery (MIGS) device, in the Netherlands. Patients were successfully implanted at the University Eye Clinic of the Maastricht University Medical Center+ b
- ECM Therapeutics Collaborates with the University of Pittsburgh Vision Institute to Advance Technology for Optic Nerve Repairhttps://modernod.com/news/ecm-therapeutics-collaborates-with-the-university-of-pittsburgh-vision-institute-to-advance-technology-for-optic-nerve-repair/2482023/ECM Therapeutics announced a collaboration with the Louis J. Fox Center for Vision Restoration at the UPMC and Pitt Vision Institute to leverage a platform technology called Matrix Bound Nanovesicles (MBV) that has recently shown potential to promote restoration of injure